104 related articles for article (PubMed ID: 29029731)
1. Dual-target inhibitor screening against thrombin and factor Xa simultaneously by mass spectrometry.
Xu Z; Liu R; Guan H
Anal Chim Acta; 2017 Oct; 990():1-10. PubMed ID: 29029731
[TBL] [Abstract][Full Text] [Related]
2. An online dual-enzyme co-immobilized microreactor based on capillary electrophoresis for enzyme kinetics assays and screening of dual-target inhibitors against thrombin and factor Xa.
Wu ZY; Zhang H; Yang YY; Yang FQ
J Chromatogr A; 2020 May; 1619():460948. PubMed ID: 32059867
[TBL] [Abstract][Full Text] [Related]
3. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
Wong PC; Jiang X
Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
[TBL] [Abstract][Full Text] [Related]
4. Direct thrombin inhibitors and factor xa inhibitors can influence the diluted prothrombin time used as the initial screen for lupus anticoagulant.
Olah Z; Szarvas M; Bereczky Z; Kerenyi A; Kappelmayer J; Boda Z
Arch Pathol Lab Med; 2013 Jul; 137(7):967-73. PubMed ID: 23808469
[TBL] [Abstract][Full Text] [Related]
5. An integration strategy combined progressive multivariate statistics with anticoagulant activity evaluation for screening anticoagulant quality markers in Chinese patent medicine.
Du KZ; Cui Y; Chen S; Yang R; Shang Y; Wang C; Yan Y; Li J; Chang YX
J Ethnopharmacol; 2022 Apr; 287():114964. PubMed ID: 34990765
[TBL] [Abstract][Full Text] [Related]
6. Microfluidic Chip-Based Online Screening Coupled to Mass Spectrometry: Identification of Inhibitors of Thrombin and Factor Xa.
Iyer JK; Otvos RA; Kool J; Kini RM
J Biomol Screen; 2016 Feb; 21(2):212-20. PubMed ID: 26323281
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of thrombin generation in plasma by inhibitors of factor Xa.
Prasa D; Svendsen L; Stürzebecher J
Thromb Haemost; 1997 Oct; 78(4):1215-20. PubMed ID: 9364987
[TBL] [Abstract][Full Text] [Related]
8. Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine-A Multicenter Trial.
Harenberg J; Beyer-Westendorf J; Crowther M; Douxfils J; Elalamy I; Verhamme P; Bauersachs R; Hetjens S; Weiss C;
Thromb Haemost; 2020 Jan; 120(1):132-140. PubMed ID: 31705521
[TBL] [Abstract][Full Text] [Related]
9. Cooperative antithrombotic effect from the simultaneous inhibition of thrombin and factor Xa.
Giardino EC; Haertlein BJ; de Garavilla L; Costanzo MJ; Damiano BP; Andrade-Gordon P; Maryanoff BE
Blood Coagul Fibrinolysis; 2010 Mar; 21(2):128-34. PubMed ID: 20010091
[TBL] [Abstract][Full Text] [Related]
10. A new peptide (Ruviprase) purified from the venom of Daboia russelii russelii shows potent anticoagulant activity via non-enzymatic inhibition of thrombin and factor Xa.
Thakur R; Kumar A; Bose B; Panda D; Saikia D; Chattopadhyay P; Mukherjee AK
Biochimie; 2014 Oct; 105():149-58. PubMed ID: 25038567
[TBL] [Abstract][Full Text] [Related]
11. Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation.
Molenaar PJ; Dinkelaar J; Leyte A
Clin Chem Lab Med; 2012 Oct; 50(10):1799-807. PubMed ID: 23089710
[TBL] [Abstract][Full Text] [Related]
12. At-line nanofractionation with parallel mass spectrometry and bioactivity assessment for the rapid screening of thrombin and factor Xa inhibitors in snake venoms.
Mladic M; Zietek BM; Iyer JK; Hermarij P; Niessen WM; Somsen GW; Kini RM; Kool J
Toxicon; 2016 Feb; 110():79-89. PubMed ID: 26708656
[TBL] [Abstract][Full Text] [Related]
13. The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.
Samama MM
Thromb Res; 2011 Jun; 127(6):497-504. PubMed ID: 20888031
[TBL] [Abstract][Full Text] [Related]
14. A validated high-throughput UHPLC-MS/MS assay for accurate determination of rivaroxaban in plasma sample.
Iqbal M; Khalil NY; Imam F; Khalid Anwer M
J Thromb Thrombolysis; 2015 Jan; 39(1):79-88. PubMed ID: 25106734
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of anthranilamide-based derivatives as FXa inhibitors.
Huang C; Wang W; Li Y; Zhang S; Meng F; Xu W; Yuan J; Chen L
Oncotarget; 2017 Jun; 8(23):37186-37199. PubMed ID: 28415603
[TBL] [Abstract][Full Text] [Related]
16. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.
Ebner M; Birschmann I; Peter A; Spencer C; Härtig F; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
Crit Care; 2017 Feb; 21(1):32. PubMed ID: 28196509
[TBL] [Abstract][Full Text] [Related]
17. Determination of rivaroxaban in patient's plasma samples by anti-Xa chromogenic test associated to High Performance Liquid Chromatography tandem Mass Spectrometry (HPLC-MS/MS).
Derogis PB; Sanches LR; de Aranda VF; Colombini MP; Mangueira CL; Katz M; Faulhaber AC; Mendes CE; Ferreira CE; França CN; Guerra JC
PLoS One; 2017; 12(2):e0171272. PubMed ID: 28170419
[TBL] [Abstract][Full Text] [Related]
18. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
[TBL] [Abstract][Full Text] [Related]
19. Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study.
Harenberg J; Du S; Wehling M; Zolfaghari S; Weiss C; Krämer R; Walenga J
Clin Chem Lab Med; 2016 Feb; 54(2):275-83. PubMed ID: 26167981
[TBL] [Abstract][Full Text] [Related]
20. Comparison of methods to determine rivaroxaban anti-factor Xa activity.
Rathbun S; Tafur A; Grant R; Esmon N; Mauer K; Marlar RA
Thromb Res; 2015 Feb; 135(2):394-7. PubMed ID: 25476589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
